Tel. : 01 45 33 67 17 / E-mail : coger@coger.fr
AVANTI POLAR LIPIDS , CYGNUS , LARODAN , ADIPOGEN , MYBIOSOURCE , SERVA NORDMARK, BIOWORLD, EDGEBIO , PANREAC APPLICHEM
Ajouter au panier
Le produit a été ajouté au panier Le stock est insuffisant. unités ont été rajoutées au panier Total:
|
Stock épuisé.
En rupture de stock
|
Quantité minimum d'achat
La quantité minimum d'achat n'est pas atteinte
|
photos non contractuelles
Product description: Inhibition of mixed lineage kinase 3 (MLK-3) is a potential strategy for the treatment of Parkinson's disease and HIV-1 associated neuro-cognitive disorders (HAND), requiring an inhibitor that can achieve significant brain concentration levels. URMC-099 is an orally bioavailable MLK-3 inhibitor with excellent brain exposure in mouse PK models and minimal interference with key human CYP450 enzymes or hERG channels. URMC-099 inhibits multiple kinase pathways, including MLK-3 (14nM) and leucine-rich repeat serine/threonine-protein kinase 2 (LRRK2) (11nM).
Alternate Names/Synonyms: 3-(1H-Indol-5-yl)-5-(4-(4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrrolo[2,3- b]pyridine
Product Type: Chemical
Molecular Formula: C27H27N5
Molecular Weight: 421.5
CAS: 1229582-33-5
Purity: >95% (HPLC)
InChiKey: QKKIWEILHCXECO-UHFFFAOYSA-N
Appearance Solid.
Solubility: Soluble in DMSO or water.
Short Term Storage: +4°C
Long Term Storage: -20°C
Shipping: AMBIENT
Use & Stability: Stable for at least 3 years after receipt when stored at -20°C.
Alerte
Veuillez saisir les champs obligatoires! |